
All News
All series
All All News
Advertisement



Gazyva may become a standard treatment for older, sicker patient with CLL.

Patients with multiple myeloma fare better with continuous Revlimid (lenalidomide).





The Memory and Attention Adaptation Training (MAAT) program was designed to improve the quality of life and function of cancer survivors who are experiencing post-therapy cognitive issues.



Brain cancer researchers and advocates join resources to help tackle this rare and aggressive malignancy.



Patients battling cancer get financial assistance from friends, family, social media and non-profit organizations.














Advertisement
Advertisement
Trending on CURE
1
FDA Updates Safety Warnings for Common Chemotherapy Drugs
2
New Combination Treatment Approach Studied in Pancreatic Cancer
3
U.S. Soccer Legend Kasey Keller Reveals Lymphoma Journey
4
Why Is Lung Health Key to Survivorship After Cancer Treatment?
5








